Mature Response Data from A Phase 2 study of PI3K-Delta Inhibitor Idelalisib in patients with Double (Rituximab and Alkylating agent)-Refractory indolent B-cell Non-Hodgkin Lymphoma (iNHL)
2014
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
6
Citations
NaN
KQI